KLRK1 and cancer: Since the killing properties of NKG2D CAR-T cells on cancers, such as leukemia (Li et al., 2022[57]), colorectal (Deng et al., 2019[23]), and cervical cancer (Zhang et al., 2020[131]) are revealed, it is expected an increased response in OS patients.